BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 24875621)

  • 1. Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program.
    Jin HJ; Zhao JC; Wu L; Kim J; Yu J
    Nat Commun; 2014 May; 5():3972. PubMed ID: 24875621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype.
    Robinson JL; Hickey TE; Warren AY; Vowler SL; Carroll T; Lamb AD; Papoutsoglou N; Neal DE; Tilley WD; Carroll JS
    Oncogene; 2014 Dec; 33(50):5666-74. PubMed ID: 24292680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer.
    Sahu B; Laakso M; Ovaska K; Mirtti T; Lundin J; Rannikko A; Sankila A; Turunen JP; Lundin M; Konsti J; Vesterinen T; Nordling S; Kallioniemi O; Hautaniemi S; Jänne OA
    EMBO J; 2011 Sep; 30(19):3962-76. PubMed ID: 21915096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer.
    Jones D; Wade M; Nakjang S; Chaytor L; Grey J; Robson CN; Gaughan L
    Oncotarget; 2015 Oct; 6(30):29782-94. PubMed ID: 26336819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXA1 acts upstream of GATA2 and AR in hormonal regulation of gene expression.
    Zhao JC; Fong KW; Jin HJ; Yang YA; Kim J; Yu J
    Oncogene; 2016 Aug; 35(33):4335-44. PubMed ID: 26751772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Darolutamide antagonizes androgen signaling by blocking enhancer and super-enhancer activation.
    Baumgart SJ; Nevedomskaya E; Lesche R; Newman R; Mumberg D; Haendler B
    Mol Oncol; 2020 Sep; 14(9):2022-2039. PubMed ID: 32333502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crosstalk between androgen and pro-inflammatory signaling remodels androgen receptor and NF-κB cistrome to reprogram the prostate cancer cell transcriptome.
    Malinen M; Niskanen EA; Kaikkonen MU; Palvimo JJ
    Nucleic Acids Res; 2017 Jan; 45(2):619-630. PubMed ID: 27672034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shaping Chromatin States in Prostate Cancer by Pioneer Transcription Factors.
    Hankey W; Chen Z; Wang Q
    Cancer Res; 2020 Jun; 80(12):2427-2436. PubMed ID: 32094298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer.
    Wu D; Sunkel B; Chen Z; Liu X; Ye Z; Li Q; Grenade C; Ke J; Zhang C; Chen H; Nephew KP; Huang TH; Liu Z; Jin VX; Wang Q
    Nucleic Acids Res; 2014 Apr; 42(6):3607-22. PubMed ID: 24423874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
    Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
    Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SUMO ligase PIAS1 functions as a target gene selective androgen receptor coregulator on prostate cancer cell chromatin.
    Toropainen S; Malinen M; Kaikkonen S; Rytinki M; Jääskeläinen T; Sahu B; Jänne OA; Palvimo JJ
    Nucleic Acids Res; 2015 Jan; 43(2):848-61. PubMed ID: 25552417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor-independent function of FoxA1 in prostate cancer metastasis.
    Jin HJ; Zhao JC; Ogden I; Bergan RC; Yu J
    Cancer Res; 2013 Jun; 73(12):3725-36. PubMed ID: 23539448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells.
    Krause WC; Shafi AA; Nakka M; Weigel NL
    Int J Biochem Cell Biol; 2014 Sep; 54():49-59. PubMed ID: 25008967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner.
    Tam KJ; Dalal K; Hsing M; Cheng CW; Khosravi S; Yenki P; Tse C; Peacock JW; Sharma A; Chiang YT; Wang Y; Cherkasov A; Rennie PS; Gleave ME; Ong CJ
    Oncotarget; 2017 Feb; 8(6):9617-9633. PubMed ID: 28038451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of p53 expression modifies the specificity of chromatin binding by the androgen receptor.
    Guseva NV; Rokhlin OW; Bair TB; Glover RB; Cohen MB
    Oncotarget; 2012 Feb; 3(2):183-94. PubMed ID: 22383394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells.
    Sahu B; Laakso M; Pihlajamaa P; Ovaska K; Sinielnikov I; Hautaniemi S; Jänne OA
    Cancer Res; 2013 Mar; 73(5):1570-80. PubMed ID: 23269278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer.
    He Y; Lu J; Ye Z; Hao S; Wang L; Kohli M; Tindall DJ; Li B; Zhu R; Wang L; Huang H
    Nucleic Acids Res; 2018 Feb; 46(4):1895-1911. PubMed ID: 29309643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOXA1 promotes tumor progression in prostate cancer via the insulin-like growth factor binding protein 3 pathway.
    Imamura Y; Sakamoto S; Endo T; Utsumi T; Fuse M; Suyama T; Kawamura K; Imamoto T; Yano K; Uzawa K; Nihei N; Suzuki H; Mizokami A; Ueda T; Seki N; Tanzawa H; Ichikawa T
    PLoS One; 2012; 7(8):e42456. PubMed ID: 22879989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Foxa1 and Foxa2 interact with the androgen receptor to regulate prostate and epididymal genes differentially.
    Yu X; Gupta A; Wang Y; Suzuki K; Mirosevich J; Orgebin-Crist MC; Matusik RJ
    Ann N Y Acad Sci; 2005 Dec; 1061():77-93. PubMed ID: 16467259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canonical and Nuclear mTOR Specify Distinct Transcriptional Programs in Androgen-Dependent Prostate Cancer Cells.
    Chen Y; Han L; Dufour CR; Alfonso A; Giguère V
    Mol Cancer Res; 2024 Feb; 22(2):113-124. PubMed ID: 37889103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.